日本薬理学会年会要旨集
Online ISSN : 2435-4953
WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology)
セッションID: WCP2018_PO2-10-21
会議情報

Poster session
Transition metal complexes/organometallic compounds as anticancer/anti HIV drugs or in pharmaceutical industry
Prakash M Kinthada
著者情報
会議録・要旨集 オープンアクセス

詳細
抄録

Abstract

Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum based drugs and Non Platinum based drugs is a Multi-Million Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. We provide a summarized synthesis and structural determination of Curcumin Oxime, Curcumin Thiosemicarbazone derivative of Gold (III) complex. The use of these analogs for prevention of cancer tumor progression and treatments of human malignancies. A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Au (III) complex and other complexes of Platinum, Palladium, Ruthenium, Copper etc.

My talk would mainly encompass different Transition Metal

We have synthesized and characterized several phytochemicals from Traditional Medicinal Plants and isolated some phytochemicals and made the corresponding Oximes, Thiosemicarbazones and Substituted thiosemicarbazones as ligands and synthesized, characterized, structurally elucidated their Transition Metal Complexes especially with Gold, Platinum, Palladium, Ruthenium, Copper etc. and Studied their Anticancer Activity, Nuclease activity etc. and tested their potential as Anticancer Drugs.

The main aim of our extensive/preclinical Pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal complexes/compounds of phytochemicals, flavanoids etc., which have very interesting structural features and properties and hence are excellent candidates as Anti-Cancer and Anti-HIV drugs .The main aim of our research is Design ,Development and Synthesis of Transition Metal Complexes/ Organometallic Compounds that would certainly help to bring this force of nature from BENCH to BEDSIDE and enhance Cancer Killing with less toxic effects and would certainly lead to initiation of clinical trials.

著者関連情報
© 2018 The Authors(s)
前の記事 次の記事
feedback
Top